Gradualism In US Health Care Reform

28 April 1996

While gradualism seems to have won the day when it comes to health care reform in the USA, there are still many doubts about the merits of such an approach.

Many of those who have said that gradual steps rather than a complete overhaul of the system would cause more problems than they solved have now become enamored of the step-by-step methods, while some of those who supported an incremental approach rather than the Clinton overhaul package several years ago are now saying they are unsure that this is the best way to proceed, reports the New York Times. Still, the changing opinions are not likely to affect the reform's chances for passage in an election year, the NYT notes.

Others feel that the Kassebaum-Kennedy insurance reform bill would not have been possible without the lessons learned several years ago. Some are more pragmatic, and note that with major reform unlikely, incremental reform has to be viewed as progress, and pursued. The bill's modesty was a feature point, according to Senator Nancy Kassebaum, while Senator John Chafee said that trying to do too much in 1993 and 1994 meant that nothing was accomplished in the end.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight